Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain.

Authors: Meng, Yu; Sohar, Istvan; Sleat, David E; Richardson, Jason R; Reuhl, Kenneth R; Jenkins, Robert B; Sarkar, Gobinda; Lobel, Peter

Published In Mol Ther, (2014 Mar)

Abstract: The blood-brain barrier (BBB) presents a major challenge to effective treatment of neurological disorders, including lysosomal storage diseases (LSDs), which frequently present with life-shortening and untreatable neurodegeneration. There is considerable interest in methods for intravenous delivery of lysosomal proteins across the BBB but for the most part, levels achievable in the brain of mouse models are modest and increased lifespan remains to be demonstrated. In this study, we have investigated delivery across the BBB using a mouse model of late-infantile neuronal ceroid lipofuscinosis (LINCL), a neurodegenerative LSD caused by loss of tripeptidyl peptidase I (TPP1). We have achieved supraphysiological levels of TPP1 throughout the brain of LINCL mice by intravenous (IV) coadministration of recombinant TPP1 with a 36-residue peptide that contains polylysine and a low-density lipoprotein receptor binding sequence from apolipoprotein E. Importantly, IV administration of TPP1 with the peptide significantly reduces brain lysosomal storage, increases lifespan and improves neurological function. This simple "mix and inject" method is immediately applicable towards evaluation of enzyme replacement therapy to the brain in preclinical models and further exploration of its clinical potential is warranted.

PubMed ID: 24394185 Exiting the NIEHS site

MeSH Terms: Administration, Intravenous; Aminopeptidases/metabolism*; Animals; Apolipoproteins E/metabolism*; Blood-Brain Barrier/metabolism*; CHO Cells; Cricetulus; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism*; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Replacement Therapy; Humans; Lysosomes/metabolism; Mice; Neuronal Ceroid-Lipofuscinoses/drug therapy*; Neuronal Ceroid-Lipofuscinoses/pathology; Neuronal Ceroid-Lipofuscinoses/physiopathology*; Peptides/administration & dosage*; Recombinant Proteins; Serine Proteases/metabolism*

Back
to Top